In some patients with newly diagnosed acute myeloid leukemia (AML) or with type 2 myelodysplastic syndrome with excess blasts (MDS-EB2), mutations have been identified in enzymes (IDH1 or IDH2). These mutations encourage the development of leukemic cells.

A number of active substances are currently in development that inhibit the mutant IDH1 and IDH2 proteins and that it is hoped will improve the treatment of patients with AML or MDS-EB2. The two active substances ivosidenib and enasidenib have been approved in the USA since 2018 and 2017 respectively. Both active substances showed good efficacy and tolerability in this patient group in clinical trials.

Various trials are currently taking place on these two medicines, such as HOVON 150. This trial is investigating whether ivosidenib and enasidenib can improve treatment outcomes in patients with newly diagnosed AML or MDS-EB2 and IDH1 or IDH2 mutation.

Adult patients (18 and above) with newly diagnosed AML or MDS-EB2 and a proven IDH1 or IDH2 mutation can take part in this trial.